<div id="readability-page-1"><div>FutureTech II Acquisition Corp., a blank check company formed to effectuate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, has released its Form 10-Q report for the second quarter of 2025. The report provides a detailed overview of the company's financial performance and key business activities during the period. Financial Highlights Net Income:<ul><li>For the three months ended June 30, 2025, the company reported net losses of $80,647, which consisted of investment income of $72,477, partially offset by expenses of $138,735 and tax expense of $14,389.</li><li>For the six months ended June 30, 2025, the company reported net losses of $370,320, which consisted of investment income of $272,304, partially offset by expenses of $592,572 and tax expense of $50,052.</li></ul>Net Income Per Share:<ul><li>For the three months ended June 30, 2025, basic and diluted net income (loss) per share of common stock was $(0.19) for redeemable shares and $(0.04) for non-redeemable shares.</li><li>For the six months ended June 30, 2025, basic and diluted net income (loss) per share of common stock was $(0.04) for redeemable shares and $(0.15) for non-redeemable shares.</li></ul>Liquidity and Capital Resources:<ul><li>As of June 30, 2025, the company had $160,723 in cash and no cash equivalents, with cash used in operating activities amounting to $1,187,204 for the six months ended June 30, 2025.</li></ul>Cash Provided by Investing Activities:<ul><li>For the six months ended June 30, 2025, cash provided by investing activities was $17,585,764 due to cash withdrawn from the Trust Account of $17,822,230, partially offset by cash deposited into the Trust Account of $236,466.</li></ul>Cash Used in Financing Activities:<ul><li>For the six months ended June 30, 2025, cash used in financing activities was $16,294,605 due to $17,400,674 in cash paid for redemptions, partially offset by proceeds from Transfer Agent of $695,024 and proceeds from issuance of debt – related party of $411,045.</li></ul> Business Highlights Business Overview: FutureTech II Acquisition Corp is a blank check company formed to effectuate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company is an emerging growth company and is subject to the associated risks.Extension of Combination Period: The company has extended its business combination period multiple times, with the latest extension allowing it to consummate its initial business combination by August 18, 2025. This extension is facilitated by monthly deposits into the trust account.Merger Agreement with Longevity Biomedical Inc.: FutureTech II has entered into a merger agreement with Longevity Biomedical Inc., which involves Longevity merging with a subsidiary of FutureTech II, becoming a wholly-owned subsidiary. The company's common stock is expected to list on NASDAQ under the ticker symbol 'LBIO' post-merger.PIPE Subscription Agreement: The company entered into a subscription agreement with an investor for the purchase of 1,000,000 shares of Class A Common Stock at $5.00 per share, contingent upon the consummation of the business combination with Longevity.Sponsor Working Capital Loans: To finance transaction costs related to the Longevity Business Combination and ongoing operations, the company issued a promissory note to the sponsor for up to $1,500,000.Compliance with Nasdaq Listing Standards: The company faced challenges in meeting Nasdaq's listing standards, resulting in a transfer from the Nasdaq Global Market to the Nasdaq Capital Market. The company is now trading over the counter following a delisting notice due to not completing a business combination within the required timeframe.Zero Interest Convertible Notes: The company issued zero interest convertible notes totaling $1,025,000 to several investors, with the option to convert the principal amount into shares of the company post-business combination.Future Outlook: The company is focused on completing its business combination with Longevity Biomedical Inc. and has extended its business combination period to ensure sufficient time for the transaction. The company is also working on regaining compliance with listing standards and expects its securities to be quoted on the over-the-counter market.SEC Filing: FutureTech II Acquisition Corp. [ FTII ] - 10-Q - Aug. 22, 2025</div></div>

FTIIU

FTII

FutureTech II Acquisition Corp. has released its SEC Form 10-Q report for Q2 2025, reporting net losses of $80,647 for the quarter and $370,320 for the six months. The company has extended its business combination period to August 18, 2025, and entered a merger agreement with Longevity Biomedical Inc. FutureTech II is also facing compliance challenges with Nasdaq listing standards and has issued zero interest convertible notes totaling $1,025,000. The company aims to complete the merger and regain compliance with listing standards.

FutureTech II Acquisition Corp. SEC 10-Q Report